Nattel Stanley, Kneller James, Zou Renqiang, Leon L Joshua
Department of Medicine and Research Center, University of Montreal, Montreal, Canada.
J Cardiovasc Electrophysiol. 2003 Oct;14(10 Suppl):S133-9. doi: 10.1046/j.1540.8167.90302.x.
Sodium channel blocking drugs (Class I antiarrhythmic agents) have been used for the termination of atrial fibrillation (AF) and for sinus rhythm maintenance for almost 100 years. Despite this long history, the mechanisms that underlie their efficacy in AF remain poorly understood. Classic notions about the determinants of cardiac reentry, as embodied in leading circle theory, and of AF, as reflected in the multiple wavelet hypothesis, suggest that cardiac conduction slowing should promote, rather than prevent, AF. This article reviews the evidence (both clinical and experimental) for the efficacy and mechanisms of action of Class I antiarrhythmic agents in AF. Application of mathematical models of AF to the evaluation of Class I mechanisms is discussed, and recent insights into the latter are presented. A better understanding of the ways in which Na+ channel blockers affect AF will be useful, not only for new antiarrhythmic drug development but also for gaining insight into the mechanisms of the arrhythmia.
钠通道阻滞剂(I类抗心律失常药物)用于终止心房颤动(AF)和维持窦性心律已有近100年历史。尽管使用历史悠久,但其在AF中发挥疗效的机制仍未完全明了。主导环理论所体现的关于心脏折返决定因素的经典概念,以及多子波假说所反映的AF概念,表明心脏传导减慢应促进而非预防AF。本文综述了I类抗心律失常药物在AF中的疗效及作用机制的证据(包括临床和实验证据)。讨论了AF数学模型在I类机制评估中的应用,并介绍了对后者的最新见解。更好地理解钠通道阻滞剂影响AF的方式不仅有助于新型抗心律失常药物的研发,还能深入了解心律失常的机制。